Post-Trial Access to ATH434 for Patients With Multiple System Atrophy

Summary

This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation by their treating physicians.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications